C-reactive protein and lipoprotein-associated phospholipase A2: new facts and possibilities for diagnostics and stratification of cardiovascular risks
Review discusses the modern concepts concerning the diagnostic role of high sensitive CRP (hsСРБ) and lipoprotein-associated phospholipase A2. Elevation of hsCRP is a key pathogenetic event, a "cross-road" leading to several events - endothelial disfunction, thrombi formation, insulin resistance, disorders of leptin, adoponectin and cytokines' function. Lipoprotein-associated phospholipase A2 elevation is specific for only vascular type of inflammation. In contrast to CRP, lipoprotein-associated phospholipase A2 is not produced in different types of systemic inflammation. It was shown, that lipoprotein-associated phospholipase A2 is an independent from low density lipoproteins level predictor of ischemic stroke. Evaluation of both markers may be effectively used for evaluation of cardiovascular risks in general population and in patients with cardiovascular diseases, as well as for evaluation of atherosclerosis presence and severity.